N/A N=141 Guided Self-help for Common Mental Disorders
Bibliotherapy
Primary: 6-week Change in Kessler 6 Psychological Distress Scale (K6) — -5.68 score on a scale (K6)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=40 Noninvasive Biomarkers of Metabolic Liver Disease 1.1
Nonalcoholic Steatohepatitis · Nonalcoholic Fatty Liver
Primary: Evaluation of Pooled Different-day, Different-operator Reproducibility of Shear Wave Speed Measurements — 30.7 Reproducibility coefficient (in %)
N/A N=563 Early Childhood Outside (ECO) - Randomized Controlled Trial Study
Risk Assessment · Online Intervention · Child Development
Primary: Change in Tolerance of Risk in Play Across Baseline, 1-week Post-intervention and 3-months Post-intervention — 0.040; -0.040; -0.156; 0.262 score on a scale
Phase 1 N=2 Blood-Stage Plasmodium Vivax Cell Bank
Malaria
Primary: P. Vivax Blood Collection — 2 Participants
Phase 3 N=6,263 Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.
Heart Failure With Preserved Ejection Fraction
Primary: Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure. — 512; 610 Participants — p=0.0008
Phase 3 N=452 Long-term Study of Efficacy/Safety of Adapalene/Benzoyl Peroxide Topical Gel in Acne Vulgaris Subjects
Acne Vulgaris
Primary: Percent Change From Baseline in Inflammatory, Noninflammatory and Total Lesion Count at Month 12 LOCF — -59.70; -58.80; -58.85 percent change
Phase 3 N=288 Maintenance Effect of Clobex Shampoo on Participants With Moderate to Severe Scalp Psoriasis
Scalp Psoriasis
Primary: Maintenance Phase: Time to First Relapse — 93.5; 56.8 days
Phase 4 N=79 Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal
Acute Bleeding on Long-Term Anticoagulation Therapy · Hemorrhage · Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time)
Primary: Number of Participants Who Demonstrated Significant Reversal of INR Within 15 Minutes — 21; 33 Participants
Phase 4 N=54 Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis
Dermatitis Atopic
Primary: Change From Baseline in Intraepidermal Nerve Fiber Density on Lesional Skin at Week 17 — 8.4567; 4.2618 F/mm^2
Phase 2 N=48 Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide
Chemo-radiation Induced Nausea and Vomiting
Primary: Complete Response (CR) Rate as Measured by Antiemesis Tool (MAT) — 0.5717; 0.7368 proportion of participants — p=0.2734
Phase 3 N=86 A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)
Cystic Fibrosis
Primary: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 61; 4 Participants
Phase 2 N=56 Hypofractionation Proton Beam Therapy With Concurrent Treatment of Prostate and Pelvic Nodes for Prostate Cancer
Prostate Cancer
Primary: Late Grade ≥ 3 Gastrointestinal (GI) and Genitourinary (GU) Toxicity of Interest, Using the CTCAE v4.0 — 1; 0 Participants
Phase 2 N=61 Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
Pancreatic Cancer
Primary: Objective Response Rate (ORR) Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1) — 0; 2 Participants
N/A N=13 Understanding Visual Confusion Using Stereoscopic Displays
Diplopia · Binocular Vision Suppression · Binocular; Fusion, With Defective Stereopsis
Primary: Percentage of Total Viewing Time That Peripheral Target is Perceived — 73.56; 59.64; 87.81 Percentage of Time — p=<0.01
Phase 4 N=16 Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs)
Urea Cycle Disorder
Primary: Rate of Treatment Success (Percentage of Participants Defined as Treatment Success at Week 4) During the Initial Treatment Period — 81.8; 80.0 percentage of participants…